Our Advisory Board

After studying clinical pharmacy at the University of Washington in Seattle, Mr. Vetter worked for five years as a pharmacist at the pharmaceutical company Schering-Plough Corp. (now Merck & Co Inc.), where he was responsible for setting up production facilities in Puerto Rico. Subsequently, he was Vice President for licensing and production at Martec, Inc., and President of Vetter Pharm-Turm Inc. Since 1987, he has held various senior management positions at Vetter and has been chairman of the board since 2008. He also established the investment company UV-Cap in 2003.

Today, Mr. Vetter is a member of the supervisory board of Gland Pharma/India and of the expert association ISPE. He was also chairman of the university council of the University Albstadt-Sigmaringen until 2018, and received the title of Honorary Senator. In 2012, he became Vice President of the association Die Familienunternehmer in Germany and, in May 2019, was named President of European Family Businesses (EFB) in Brussels.

After receiving a PhD in Clinical Pharmacy and stays in the USA and UK, Dr. Cornelia Vetter-Kerkhoff established a drug information center for complex inquiries regarding drug therapy in the hospital pharmacy at the University Hospital of Munich (LMU). Since 1993, she is actively involved in the German hospital pharmacist association. From 2003 to 2019, she chaired the Drug Information Committee and initiated 2007 with this group the biennial German Congress of Drug Information. In 2009, she was awarded the association's honorary pin for special contributions in the field of hospital pharmacy. Since 2012, Cornelia Vetter-Kerkhoff actively promotes research activities in the field of clinical pharmacy and personalized drug therapy safety in Germany.

PD Dr. Ute Amann studied pharmacy at the Freie Universität Berlin and graduated at the LMU Munich as Master of Public Health. After several years in public pharmacies in Germany and New Zealand, she worked as a clinical pharmacist at the university hospitals in Freiburg and Munich, at the Bavarian Association of Statutory Health Insurance Physicians, and also at a company for healthcare data management. From 2003 onwards, she consults on medical pharmaceutical and pharmacoepidemiologic matters initially in industry and later also in research. From 2010 to 2023 she worked as a scientist, at the Leibniz Institute for Prevention Research and Epidemiology – BIPS in Bremen and at the KORA Myocardial Infarction Registry of the Helmholtz Zentrum München, German Research Center for Environmental Health. Ute Amann qualified as professor for epidemiology at the Medical Faculty of LMU Munich and is a lecturer in pharmacoepidemiology at the LMU.

Dr. Axel Herberg is a private investor in corporate and real estate investments and a member of several supervisory boards at healthcare and pharmaceutical companies. From 2010 to 2017, he was partner and then from 2017 to 2019 senior advisor at the investment company Blackstone Group. Prior to that, Dr. Herberg held various management positions at Gerresheimer AG in Germany and abroad since 1992, including 10 years as CEO. In May 2015, he was elected Chairman of the Supervisory Board for the Gerresheimer Group, having already been a member of the Supervisory Board since 2014. Previously, he worked as consultant at McKinsey & Company and as Head of Strategic Planning at Krupp Industrietechnik. Dr. Herberg holds a doctorate in Business Administration and a Mechanical Engineering degree.

An expert in  company and tax law, Prof. Dr. Hettich joined the Mannheim-based law firm Rittershaus in 1990. There, he specialized in corporate structure development and was named partner within three years. Among other roles, he is both a member and chairman of the supervisory boards of several listed companies, as well as founder and managing director of Dievini Hopp Biotech Holding.

Mr. Kerkhoff studied business, politics, and journalism in Munich and Montpellier, France. A professional congress organizer since 1984, he organizes medically-focused events throughout Europe for both industry and scientific organizations. Since 1990, he has served as managing partner for Eurokongress, and in 1995, he became the first German citizen to be certified as a congress organizer by the worldwide association MPI. He has been senior partner there since 2012.

Mr. Kerkhoff is also a member of the board of the Munich Congress Alliance and President of Asconet International.

Mr. Moelgaard has a background as a process automation engineer, and worked at Novo Nordisk and Novo Nordisk Engineering from 1982 to 2016. He has held a range of senior management positions, including Corporate Vice President for Pharmaceutical Engineering, Consulting, and Strategic Development in NNE Pharmaplan A/S.

Since 2016, Mr. Moelgaard has worked as an independent senior consultant at Moelgaard Consulting. He has also been a member or leader of several international committees and expert associations, including ISPE, PDA, ISA and others.

Since 1995, Dr. Susanne Schaffert, who holds a PhD in chemistry with honors from the University of Erlangen, served in various leadership positions at Novartis, including Head of Europe Oncology and President and Chair of Accelerated Advanced Applications. At last, she served as President Novartis Oncology and member of the Executive Committee of Novartis, responsible for the global oncology portfolio. Her achievements include the oversight of the first launched CAR-T cell therapy in hematology, to which she has provided access to people in 34 countries, and the launch of the first two radioligand therapies for the treatment of solid tumors in the US and Europe. Twice recognized by Fortune Magazine as one of the "Top 100 Most Powerful Women International," she now serves as an independent member of the boards of directors at Novo Holdings, Galapagos, Incyte as well as ARTBio and contributes her expertise as a member of the Senate Committee on Executive Education at the University of St. Gallen (Switzerland).

Mr. Strothe graduated with an MA in Economics and an MBA from Freiburg/Br. and Fontainebleau. From 1976 to 1990, he worked as a qualified accountant for international accounting firms in both Germany and the USA. He then served as CFO at Hugo Boss AG, as an Investment Banker at Goldman Sachs & Co and, until 2006, as Managing Director for Germany with the international consulting firm Oliver Wyman & Company. Since 1996, he has been a non-executive member of several company boards.